文献速递心外重症与机械循环支持

新型磁悬浮左心室辅助装置治疗难治性心衰的临床研究设计

Design and rationale for the clinical investigation of a novel, magnetically levitated left ventricular assist device for the treatment of refractory heart failure.
PubMed 文献 · J Heart Lung Transplant · 2025-03-08

INNOVATE试验为多中心、前瞻性、非盲、随机对照非劣效性研究,比较BrioVAD与HeartMate 3,纳入短期和长期队列。主要终点为无致残性卒中或泵置换的生存至移植、心脏恢复或支持6/24个月复合终点。

要点

  • BrioVAD为全磁悬浮泵,拟提供短期和长期机械循环支持。
  • INNOVATE试验以2:1随机比较BrioVAD与HeartMate 3的非劣效性。
  • 主要复合终点包括无致残性卒中或泵置换的生存至移植、心脏恢复或支持6/24个月。

核心结论

  • INNOVATE试验旨在评估BrioVAD相较于HeartMate 3的非劣效性安全性和有效性。

研究设计与样本

  • 多中心、前瞻性、非盲、随机(2 BrioVAD:1 HM3)、对照、非劣效性研究,设预定义安全阶段。
  • 安全队列n=45,短期队列n=237,长期队列n=402。

主要发现

  • 安全队列(n=45)预计2025年初完成入组,短期队列(n=237)预计2026年完成,长期队列(n=402)预计2027年完成。

关键数值与推荐

  • 主要终点为无致残性卒中(改良Rankin量表>3)或泵置换的生存至移植、心脏恢复或支持6个月(短期)或24个月(长期)的复合终点。
  • 次要终点评估在医院、专业护理机构或住院康复机构的天数。

临床怎么用

  • 该试验设计为评估BrioVAD独特设计特征提供框架,预期改善患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary durable left ventricular assist devices (LVAD) have established current benchmarks for patient outcomes, but introduction of more novel technology is lacking. The BrioVAD System (BrioHealth Solutions, Burlington, MA) is an innovative, fully magnetically levitated pump intended to provide short-term (ST) and long-term (LT) mechanical circulatory support. METHODS: The Investigation of a Novel, MagNetically Levitated VAD for the Treatment of RefractOry Left Ventricular HeArT FailurE Clinical Trial (INNOVATE) is designed to evaluate safety and efficacy of the BrioVAD by demonstrating non-inferiority to the HeartMate 3 (HM3; Abbott Labs, Chicago, IL). INNOVATE is a multi-center, prospective, non-blinded, randomized (2 BrioVAD: 1 HM3), controlled, non-inferiority study designed as a staged pivotal study with a pre-defined safety phase. Exclusion criteria are designed to enroll a patient population that aligns with contemporary clinical practice. Primary endpoints include a composite of survival to transplant, cardiac recovery, or 6 months (ST) or 24 months (LT) of LVAD support free from debilitating stroke (modified Rankin Scale > 3), or reoperation to replace the pump. A powered secondary outcome evaluates days spent in hospital, skilled nursing facility, or inpatient rehabilitation. RESULTS: INNOVATE study screening and enrollment began in 2024. Completed enrollment of the safety cohort (n = 45) is projected in early 2025. Completion of the ST cohort (n = 237) and LT cohort (n = 402) is projected for 2026 and 2027, respectively. CONCLUSIONS: INNOVATE represents a contemporary clinical trial design evaluating unique design features of the BrioVAD System with the expectation to improve patient outcomes.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Pagani FD, Cowger JA, Jorde UP, et al. Design and rationale for the clinical investigation of a novel, magnetically levitated left ventricular assist device for the treatment of refractory heart failure. J Heart Lung Transplant. 2025. PMID: 40064407. doi:10.1016/j.healun.2025.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。